Molecular Insights into Wnt3a and Wnt5a Gene Expression in Venous Insufficiency

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2024 Dec 16

PMID 39680245

Authors

Fatima Eltayb M Ageed

Fadumo Ali Tifow

Leylo Abdullahi Ibrahim

Aya B Ismael

Ozlem Balcioglu

Barcin Ozcem

Havva Cobanogullari

Selma Yilmaz

Mahmut Cerkez Ergoren

Affiliations

Soon will be listed here.

Abstract

Background: Chronic venous insufficiency (CVI) manifests as morphological and functional abnormalities in the venous system, primarily affecting the lower extremities and presenting as leg heaviness, oedema, and varicose veins. CVI is a common vascular disorder characterised by impaired blood flow in the veins, often leading to various clinical manifestations. To better understand the additional underlying mechanisms of CVI, it is essential to explore the role of Wnt proteins, which play a crucial role in regulating signalling processes. This study aimed to investigate the expression levels of the Wnt3a and Wnt5a genes using real-time PCR in patients with venous insufficiency compared to acontrol group.

Methods And Results: 68 participants were included, comprising 29 controls and 39 patients with venous insufficiency from Near East University Hospital. Real-time PCR was utilised for gene expression analysis on a segment of the great saphenous vein biopsy, encompassing all vascular layers, from each participant in both groups. With a significance threshold of p < 0.05, the analysis revealed a significant difference in Wnt3a gene expression (p ₌ 0.0007) and a nonsignificant difference in Wnt5a expression levels (p ₌ 0.5726) between patients with venous insufficiency and the healthy control group.

Conclusion: This study indicates fluctuations in the Wnt genes in varicose vein biopsies compared to healthy veins. Consequently, further research is essential to elucidate whether the dysregulation of the Wnt pathway induces venous insufficiency or vice versa. This may facilitate targeted interventions addressing its fundamental molecular aberrations.

References

Raju S, Neglen P . Clinical practice. Chronic venous insufficiency and varicose veins. N Engl J Med. 2009; 360(22):2319-27. DOI: 10.1056/NEJMcp0802444. View

Bergan J, Schmid-Schonbein G, Smith P, Nicolaides A, Boisseau M, Eklof B . Chronic venous disease. N Engl J Med. 2006; 355(5):488-98. DOI: 10.1056/NEJMra055289. View

Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H . The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020; 8(3):342-352. DOI: 10.1016/j.jvsv.2019.12.075. View

Escudero Rodriguez J, Fernandez Quesada F, Bellmunt Montoya S . Prevalence and clinical characteristics of chronic venous disease in patients seen in primary care in Spain: results of the international study Vein Consult Program. Cir Esp. 2013; 92(8):539-46. DOI: 10.1016/j.ciresp.2013.09.013. View

Mekky S, Schilling R, WALFORD J . Varicose veins in women cotton workers. An epidemiological study in England and Egypt. Br Med J. 1969; 2(5657):591-5. PMC: 1983630. DOI: 10.1136/bmj.2.5657.591. View

Criqui M, Denenberg J, Bergan J, Langer R, Fronek A . Risk factors for chronic venous disease: the San Diego Population Study. J Vasc Surg. 2007; 46(2):331-7. PMC: 2023874. DOI: 10.1016/j.jvs.2007.03.052. View

Dindelli M, Parazzini F, Basellini A, Rabaiotti E, Corsi G, Ferrari A . Risk factors for varicose disease before and during pregnancy. Angiology. 1993; 44(5):361-7. DOI: 10.1177/000331979304400504. View

Gourgou S, Dedieu F, Sancho-Garnier H . Lower limb venous insufficiency and tobacco smoking: a case-control study. Am J Epidemiol. 2002; 155(11):1007-15. DOI: 10.1093/aje/155.11.1007. View

Labropoulos N, Delis K, Nicolaides A . Venous reflux in symptom-free vascular surgeons. J Vasc Surg. 1995; 22(2):150-4. DOI: 10.1016/s0741-5214(95)70109-5. View

10.

Tuchsen F, Hannerz H, Burr H, Krause N . Prolonged standing at work and hospitalisation due to varicose veins: a 12 year prospective study of the Danish population. Occup Environ Med. 2005; 62(12):847-50. PMC: 1740939. DOI: 10.1136/oem.2005.020537. View

11.

Cohen E, Tian Y, Morrisey E . Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor self-renewal. Development. 2008; 135(5):789-98. DOI: 10.1242/dev.016865. View

12.

De Jaime-Soguero A, Abreu de Oliveira W, Lluis F . The Pleiotropic Effects of the Canonical Wnt Pathway in Early Development and Pluripotency. Genes (Basel). 2018; 9(2). PMC: 5852589. DOI: 10.3390/genes9020093. View

13.

Foulquier S, Daskalopoulos E, Lluri G, Hermans K, Deb A, Blankesteijn W . WNT Signaling in Cardiac and Vascular Disease. Pharmacol Rev. 2017; 70(1):68-141. PMC: 6040091. DOI: 10.1124/pr.117.013896. View

14.

Lecarpentier Y, Schussler O, Hebert J, Vallee A . Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers. Front Oncol. 2019; 9:1248. PMC: 6876670. DOI: 10.3389/fonc.2019.01248. View

15.

Hamdan A . Management of varicose veins and venous insufficiency. JAMA. 2012; 308(24):2612-21. DOI: 10.1001/jama.2012.111352. View

16.

Wo D, Peng J, Ren D, Qiu L, Chen J, Zhu Y . Opposing Roles of Wnt Inhibitors IGFBP-4 and Dkk1 in Cardiac Ischemia by Differential Targeting of LRP5/6 and β-catenin. Circulation. 2016; 134(24):1991-2007. DOI: 10.1161/CIRCULATIONAHA.116.024441. View

17.

Duchartre Y, Kim Y, Kahn M . The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 2016; 99:141-9. PMC: 5853106. DOI: 10.1016/j.critrevonc.2015.12.005. View

18.

Gordon M, Nusse R . Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006; 281(32):22429-33. DOI: 10.1074/jbc.R600015200. View

19.

Majidinia M, Yousefi B . Breast tumor stroma: A driving force in the development of resistance to therapies. Chem Biol Drug Des. 2017; 89(3):309-318. DOI: 10.1111/cbdd.12893. View

20.

Holland J, Klaus A, Garratt A, Birchmeier W . Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol. 2013; 25(2):254-64. DOI: 10.1016/j.ceb.2013.01.004. View